| pubmed-article:20948682 | pubmed:abstractText | In recent years, many potential antifibrotic treatment strategies have emerged from molecular studies of systemic sclerosis. Few biologicals have already entered clinical trials and these may hopefully prove to be effective in this progressive, profibrotic disease. | lld:pubmed |
